This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Renal cancer	DnaJ (Hsp40) homolog subfamily B member 8 (DNAJB8)	<i>In vitro</i> and mouse studies suggest blocking DNAJB8 on cancer stem cells could help treat renal cell carcinoma. In renal carcinoma cell lines, anti-DNAJB8 small interfering RNA eliminated the cancer stem cell population and decreased tumor-initiating ability compared with siRNA controls. In mice, immunization with Dnajb8 led to a greater antitumor effect against renal cell carcinomas than immunization with survivin (BIRC5), a tumor antigen expressed on both cancer stem cells and noncancer stem cells. Next steps could include testing the vaccination strategy in additional animal models.	Patent and licensing status unavailable	Nishizawa, S. <i>et al. Cancer Res.</i> ; published online May 2, 2012; doi:10.1158/0008-5472.CAN-11-3062 Contact: Yoshihiko Hirohashi, Sapporo Medical University, Sapporo, Japan e-mail: hirohash@sapmed.ac.jp
<i>SciBX</i> 5(23); doi:10.1038/scibx.2012.599 Published online June 7, 2012				